Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC

Abroad (travel likely)RecruitingPHASE2

Conditions

Esophageal Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Contact: Study coordinator (Zhao-han Lin) · xhyyllwyh@163.com · 0086-0591-86218329

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE3

Tianjin, China

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) · Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) · Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · Baltimore, United States

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell Lung · Squamous Cell Carcinoma of Head and Neck · HER2 Negative Breast Neoplasms

Abroad (travel likely)RecruitingPHASE1

Anchorage, United States · Fayetteville, United States

Tumor Regression Grade As Predictor of Adjuvant Therapy

Esophageal Squamous Cell Carcinoma (ESCC)

Abroad (travel likely)Recruiting

Fuzhou, China